Physician

Araya Kifle Negash, D.O.

According to 2025 Medicare claims, Araya Negash, D.O. (NPI: 1669793253) practices interventional cardiology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is SPECTRUM HEALTH PRIMARY CARE PARTNERS (NPI: 1235188673; TIN: 381358164) and primary practice location at 49503-2560. Negash is affiliated with the POM ACO (ACO ID: A1297) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Negash's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,534 traditional Medicare patients, billed 1,859 HCPCS/CPT codes, and received $62,377 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,850 prescription claims across 539 beneficiaries totaling $489,588 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 21 records totaling $631,503. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $35,806 and ending at $62,377. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,152 to $489,588. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	318	471	$35,806
2018	952	1,529	$97,287
2019	899	1,296	$78,857
2020	440	617	$51,935
2021	1,157	1,626	$84,445
2022	715	920	$54,715
2023	751	924	$53,116
2024	1,534	1,859	$62,377

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	84	$3,152
2016	28	72	$6,417
2017	53	137	$5,229
2018	231	913	$68,097
2019	354	1,865	$145,628
2020	388	2,094	$166,644
2021	460	2,689	$228,522
2022	530	3,208	$313,730
2023	539	2,948	$375,493
2024	539	2,850	$489,588

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	68	70	$74
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	73	74	$13
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	63	67	$10
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	137	137	$9
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	1,145	1,165	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	161	10,155	$182,783
Entresto	Sacubitril/Valsartan	73	4,090	$85,132
Jardiance	Empagliflozin	40	2,520	$46,907
Farxiga	Dapagliflozin Propanediol	46	2,247	$39,247
Brilinta	Ticagrelor	40	2,310	$31,880

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$207	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	15	$631,296	Medtronic, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Araya Kifle Negash, D.O.?

Tedicare shows public-source Medicare data for Araya Kifle Negash, D.O. (NPI 1669793253), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Araya Kifle Negash, D.O. have ACO affiliation data?

Araya Kifle Negash, D.O. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Araya Kifle Negash, D.O.?

Araya Kifle Negash, D.O. is linked to SPECTRUM HEALTH PRIMARY CARE PARTNERS (billing NPI 1235188673) in the available physician profile data.

Does Araya Kifle Negash, D.O. have Open Payments data?

Araya Kifle Negash, D.O. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.